PF 626414

Drug Profile

PF 626414

Alternative Names: PF-06260414; PF-0626414; PF-626414

Latest Information Update: 05 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cachexia

Most Recent Events

  • 28 Jul 2015 Discontinued - Phase-I for Cachexia in USA (PO)
  • 27 Apr 2015 Pfizer terminates a phase I trial (In volunteers) in USA (NCT02393807)
  • 26 Mar 2015 Pfizer plans a phase I pharmacokinetic trial for Healthy volunteers in USA (NCT02393807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top